Proteomic Capabilities Aligned to Development Programs
Proteas Health integrates quantitative proteomic workflows into therapeutic and diagnostic development to enable target engagement assessment, systemic drug response evaluation, and structured translational advancement toward clinical-scale assay deployment.
Systems-Level Proteome Characterization
High-resolution quantitative proteome and phosphoproteome profiling to resolve pathway activity, target engagement, and systemic biological response.
Blood Proteomics for Drug Response and Clinical Assay Development
Quantitative plasma proteomic analysis enabled by the BioTAS™ platform to characterize systemic drug effects, define stratification strategies, and establish protein signatures for assay translation.
Quantitative Assay Development
Multiplexed quantitative protein measurement workflows designed for translational confirmation and integration into clinical development programs, including deployment within CLIA-aligned laboratory environments.
.avif)
.avif)
.jpg)
The BioTAS™ Platform
BioTAS™ is a globally patented proteomics infrastructure (PCT/US2021/063407) integrating controlled plasma isolation, high-resolution quantitative mass spectrometry, and AI-enabled modeling to deliver reproducible protein measurement across decentralized and CLIA-aligned laboratory environments.
Platform Architecture
- Proprietary remote blood collection and plasma stabilization
- Controlled pre-analytical handling to minimize collection variability
- Quantitative mass spectrometry workflows for reproducible protein measurement
- AI-enabled proteomic data modeling and temporal pattern analysis
- Infrastructure supporting assay transfer and multi-site study integration
Built for Reproducibility and Clinical Scale
Designed for program integration rather than exploratory analysis, our workflows enable multi-site integration, reproducible protein measurement and compatibility with regulated laboratory environments.
- Inter-operator and inter-instrument reproducibility
- Low-volume plasma compatibility
- Standardized analytical workflows
- Multi-site program integration
- CLIA-aligned laboratory compatibility
Supporting Programs Across Development Stages
Drug Development
Proteomic integration from preclinical research through Phase I–III clinical trials, supporting target engagement assessment, systemic pharmacodynamic evaluation, and mechanistic validation.
Diagnostic Programs
Development and analytical validation of quantitative plasma assays supporting scalable implementation within CLIA-aligned laboratory environments.
Academic Research
Mechanistic proteomic collaboration for publication-grade biological investigation.
